The Future Medical Innovation Cooperation Forum was held, and the "Challenge and Response" list for the biomedical field in Sichuan and Chongqing was released

On November 6th, as one of the key events of the first "Belt and Road" Science and Technology Exchange Conference, the Future Medical Innovation Cooperation Forum was held at the Chongqing Yuelai International Convention Center. The forum was jointly hosted by the People's Government of Sichuan Province and the People's Government of Chongqing Municipality, with the theme of Future medical innovation cooperation. 43 foreign guests from 10 countries, as well as renowned expert representatives from high-level research hospitals around the world and across the country, attended the event.

At the forum, the attending guests focused on the innovative development of the pharmaceutical industry, future medical innovation and open cooperation models, and jointly discussed several major concerns regarding the application of innovative achievements in life sciences to people's health. At the same time, the 2023 "Challenge and Response" list for the biomedicine field in Sichuan and Chongqing was released on the spot.

Raksana Tri Handoko, Director of the National Research and Innovation Agency of Indonesia, Almando Rodriguez Battista, Deputy Minister of Science, Technology and Environment of Cuba, Zhang Guangjun, Vice Minister of Science and Technology of China, Wang Chen, Vice President and academician of the Chinese Academy of Engineering, Yang Xingping, Vice Governor of Sichuan Province, and Dan Yanzheng, Vice Mayor of Chongqing Municipality, attended the event and delivered speeches.

 

Strengthen the field of life and health, International cooperation in scientific and technological innovation

During the keynote speech session of the forum, experts such as Academician Wei Yuquan, Academician Bian Xiuwu, Academician Yang Zhenglin from the Chinese Academy of Sciences, Academician Liu Liang, Academician Fan Xianqun from the Chinese Academy of Engineering, Academician Zhang Yiguo from the European Academy of Sciences, and Olga Shangjina, the director of the Organization Library of Bashkiel State Medical University, focused on "The Application of Biotechnology in Medicine" and "Building an Innovation resource Platform". Keynote reports were made on topics such as "Building a High Ground for Intelligent Diagnosis".

Wei Yuquan said that in recent years, the development of biomedicine has received high attention and emphasis both at home and abroad. For the future development of China's biomedicine industry, it is crucial to enhance the industry's innovation capacity and the construction of an innovation system. Meanwhile, he looks forward to integrating into the global biomedical innovation system by strengthening international cooperation under the Belt and Road Initiative.

"Unearth the value of traditional Chinese medicine in the prevention and treatment of major diseases and provide a Chinese solution for the world to address the challenges of major disease prevention and treatment." " In his keynote report, Liu Liang mentioned more than once the "Chinese solution to the Challenges of major disease prevention and control". And this plan is being gradually realized in China's first national key laboratory specializing in traditional Chinese medicine - the National Key Laboratory of TCM Syndromes. In the future, the laboratory will focus on the theory of syndrome differentiation and treatment to carry out multi-disciplinary cross-integration and innovative research, and build a high-end scientific and technological innovation platform for the basic research of clinical application of traditional Chinese medicine with a globally leading level. Liu Liang said.

Bian Xiuwu believes that intelligent diagnosis will establish a unified standard large database of disease phenotypes, innovate new strategies and technologies for AI-assisted diagnosis, and further improve diagnostic efficiency. "In the future, pathological diagnosis will be integrated, integrating morphological structure with genetic changes to achieve the purpose of diagnosis." The purpose of this diagnosis is not only to examine the tumor cells, but also the blood vessels and the surrounding immune cells. It is hoped that clinicians and other relevant biological experts can cooperate more with doctors in pathology and diagnostic disciplines to jointly promote the development of integrative medicine, especially integrative diagnosis.

 

Research more innovative methods in medicine, Enhance people's health and well-being

During the high-level conversation session, experts and entrepreneurs from research institutions and enterprises such as the Scientific Practice Heart Center of the Republic of Uzbekistan, West China Hospital of Sichuan University, and Chongqing Jinfeng Laboratory focused on "Enhancing the Health and Well-being of Developing Countries through Pharmaceutical Innovation and Jointly Building a Health Community". In-depth discussions were held on two themes: "Exploring Open Innovation Cooperation Models" and "Future Medical Innovation Research Methods and Cooperation Models".

By formulating task lists, implementing an integrated design of basic research, applied basic research, and technology transfer, and conducting organized scientific research to enhance the efficiency of scientific and technological innovation, the laboratory has made landmark progress in original research on the pathogenesis of glioma and breakthroughs in key technologies that have been bottlenecks in intelligent pathological diagnosis. Xu Hui, deputy director of the Jinfeng Laboratory, said that currently, the Jinfeng Laboratory has also formulated measures for the introduction of scientific research talents, hoping that more high-level scientific research teams will join, accelerate the cultivation of strategic scientific and technological forces, form more innovative achievements with Chongqing's distinctive features, and enhance the radiation and driving force for the western region.

Regarding medical innovation, Chen Lei, the vice president of West China Hospital of Sichuan University, introduced that West China Hospital is promoting the expansion of research related to epilepsy. For instance, establishing disease resistance and rapid monitoring methods can help pregnant patients reduce the potential risks they may face. Chen Lei said, "I hope to treat epilepsy from multiple dimensions and in a systematic way from the patient's heart, intestines and other parts."

Medical innovation hinges crucially on talent cultivation. Zhang Chunxiang, a foreign academician of the European Academy of Natural Sciences and the president of Southwest Medical University, introduced that Southwest Medical University, taking the improvement of the top level of disciplines as the entry point, has accelerated the competition for the three newly added first-level discipline doctoral programs in clinical medicine, integrated traditional Chinese and Western medicine, and pharmacy, and has also accelerated the cultivation and reserve of more high-level doctoral talents capable of handling difficult and complicated diseases and medical problems. Gradually, it will represent the leading level of the region and play a leading role in the diagnosis and treatment of difficult and critical cases, the cultivation of high-level medical talents, the resolution of major public health issues, and pharmaceutical research and development, laying a solid disciplinary foundation for building a national regional medical center.

Science and innovation have played a crucial role in the pharmaceutical industry. With science and innovation, the pharmaceutical industry can create newer and more effective pharmaceutical products, improve manufacturing quality, reduce time and costs, and lower the risks for patients. Hershi Fuzilov, the director of the Scientific Practice Heart Center of the Republic of Uzbekistan, said, "We hope this forum can serve as a platform for communication between the pharmaceutical industries of Uzbekistan and China, discuss issues of common concern, exchange experiences, carry out cooperation projects, and promote the innovative development of the pharmaceutical industries in both countries."

 

Sichuan and Chongqing jointly released 16 items, List of key research projects in precision medicine

To make simultaneous efforts in promoting scientific and technological innovation and the transformation of scientific and technological achievements, four units from Chengdu and Chongqing, namely the National Precision Medicine Industry Innovation Center, Boao Sais (Chongqing) Biotechnology Co., LTD., Chongqing Defang Information Technology Co., Ltd. and Chongqing Precision Biotechnology Co., LTD., will implement the "challenge and response" system to carry out research and development on innovative projects.

At this forum, 16 projects on the "Challenge and Response" list were announced.

Among them, there are four items in the field of precision diagnosis, including single-molecule sequencing technology, second-generation gene sequencing technology, etc. Six items in the field of precision therapy, including drug screening algorithms and software based on artificial intelligence, key technologies for lead compound screening, etc. Six items in the field of precise evaluation, including key technologies of organoids and preclinical safety evaluation of innovative biotechnological drugs, etc.

It is worth noting that for the projects released this time, the maximum amount of individual support funds shall not exceed 10 million yuan (inclusive), and the implementation period shall in principle not exceed two years. The application deadline is December 6, 2023. For detailed information, please pay attention to the project application notice and guidelines.

This list covers the cutting-edge innovations and future technologies of precision medicine. It will select partners from the world's top teams to jointly tackle key problems, form a number of original achievements, break through a number of key core technologies, transform a number of scientific and technological achievements, and benefit thousands of people. Wu Yifeng, the business director of the National Precision Medicine Industry Innovation Center, said that he is very much looking forward to taking this release as an opportunity for biopharmaceutical enterprises in Sichuan and Chongqing to further deepen cooperation, complement each other's advantages, and bring more "Sichuan-made", "Chongqing-made", "Chinese brands" and "Chinese solutions" to the biopharmaceutical industry.

 

Sixteen "challenge and response" projects

(Source: Chongqing Daily, Huabang.com)